Further investigation is needed to confirm this threshold and its clinical relevance

The gap

Evidence profile

Sourced from the future work and inline gaps and limitations of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 2 journals. Those papers have been cited 20 times in total.

Supporting evidence — 3 representative gaps

• Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids: new analytical approaches (2024) · Frontiers in Nutrition · cited 14× · doi

  Reanalyzing the existing datasets from the REDUCE-IT and STRENGTH trials presents a valuable opportunity to uncover common denominators that could reconcile their divergent outcomes, or at least shed light on the mechanisms driving their discrepancies. Specifically, focusing on the effects of resting heart rate, heart rate variability, and ethnic subgroup differences in response to EPA or the combination of EPA and DHA could provide novel insights or significantly reinforce the current evidence base. Much of the research conducted thus far has been grounded in nutritional surveys or short-term dietary interventions, often with lower omega-3 dosages that may not capture the full spectrum of effects observed in large-scale clinical trials. Delving into these deeper analyses, whether undertaken by the original trial investigators or by independent experts with access to the data, could yield pivotal findings that inform future clinical guidelines. These investigations hold the potential to refine both dietary and pharmaceutical strategies for reducing major adverse cardiovascular events and addressing residual cardiovascular risk, ultimately advancing cardiovascular health and longevity. By expanding our understanding of omega-3’s pleiotropic effects through these new analytical perspectives, we can further enhance evidence-based approaches for cardiovascular disease prevention, treatment, and sustained health.

  generalfuture work
  Keywords: cardiovascular effects trials heart rate evidence dietary omega clinical health reanalyzing existing datasets reduce strength
• Dietary Omega-3 intake may slow prostate cancer progression and reduce mortality risk: evidence from prostate, lung, colorectal, and ovarian cancer screening trial (2025) · Frontiers in Nutrition · cited 6× · doi

  However, further investigation is needed to confirm this threshold and its clinical relevance. First, the collection of dietary data was limited to the baseline DHQ, which did not account for potential dietary changes during the follow- up period. In addition, the subjects of this study were mainly non-Hispanic White men in the United States aged 55–74 years, and the results may not be applicable to young men, other races or regions. Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence.

  generalinline gaps
  Keywords: dietary further investigation needed threshold clinical relevance first collection limited baseline account potential changes follow
• Comparative prognostic performance of nutritional, immune-inflammatory, and anthropometric indices for cardiovascular and all-cause mortality in older adults with cardiovascular disease (NHANES 2009–2018) (2026) · Annals of Geriatric Medicine and Research · doi

  Strengths include a nationally representative NHANES sample with National Death Index linkage and a median follow-up exceeding a decade; survey-weighted analysis with multiple imputation; and restricted cubic-spline modeling of non-linear dose–response relationships. The within-cohort comparison of three index categories provides directly comparable evidence, and sensitivity analyses (landmark, complete-case, and dietary- adjusted) converged on the same conclusions. This study has limitations. First, the cohort is heterogeneous (congestive heart failure, coronary heart disease, angina, myocardial infarction, stroke), and NHANES lacks cardiac- specific characterization such as left ventricular ejection fraction or natriuretic peptides; the 20 findings should not be extrapolated to phenotype-specific decisions without validation in cohorts with detailed cardiac phenotyping. Second, the comparison between the nutritional indices and the SII is conceptually asymmetric: the former integrate a chronic exposure and the latter reflects an acute snapshot. Third, all indices were measured at a single visit, precluding evaluation of longitudinal trajectories. Finally, despite multivariable adjustment, multiple imputation, and sensitivity analyses, residual confounding cannot be excluded.

  generallimitationsevidence 5/5
  Keywords: nhanes index multiple imputation cohort comparison sensitivity analyses heart cardiac specific indices strengths include nationally

Questions about this gap